Page 114 - 南京医科大学学报自然科学版
P. 114
第43卷第2期
·256 · 南 京 医 科 大 学 学 报 2023年2月
e284-e294 (8):1096-1102
[6] EL⁃GALALY T C,VILLA D,GORMSEN L C,et al. FDG⁃ [16] MIKHAEEL N G,SMITH D,DUNN J T,et al. Combina⁃
PET/CT in the management of lymphomas:current status tion of baseline metabolic tumour volume and early re⁃
and future directions[J]. J Intern Med,2018,284(4): sponse on PET/CT improves progression⁃free survival pre⁃
358-376 diction in DLBCL[J]. Eur J Nucl Med Mol Imaging,
[7] BARRINGTON S F,KLUGE R. FDG PET for therapy 2016,43(7):1209-1219
monitoring in Hodgkin and non⁃Hodgkin lymphomas[J]. [17] ZHOU M G,CHEN Y M,HUANG H H,et al. Prognostic
Eur J Nucl Med Mol Imaging,2017,44(Suppl 1):97-110 value of total lesion glycolysis of baseline 18F⁃fluorodeox⁃
[8] KOSTAKOGLU L,MARTELLI M,SEHN L H,et al. End⁃ yglucose positron emission tomography/computed tomog⁃
of⁃treatment PET/CT predicts PFS and OS in DLBCL af⁃ raphy in diffuse large B⁃cell lymphoma[J]. Oncotarget,
ter first ⁃ line treatment:results from GOYA[J]. Blood 2016,7(50):83544-83553
Adv,2021,5(5):1283-1290 [18] KIM C Y,HONG C M,KIM D H,et al. Prognostic value
[9] GUO R,XU P P,CHENG S,et al. Comparison of nasopha⁃ of whole⁃body metabolic tumour volume and total lesion
ryngeal MR,18F⁃FDG PET/CT,and 18F⁃FDG PET/MR glycolysis measured on 18F⁃FDG PET/CT in patients with
for local detection of natural killer/T⁃cell lymphoma,na⁃ extranodal NK/T⁃cell lymphoma[J]. Eur J Nucl Med Mol
sal type[J]. Front Oncol,2020,10:576409 Imaging,2013,40(9):1321-1329
[10] ROSSI C,TOSOLINI M,GRAVELLE P,et al. Baseline [19] CHANG Y,FU X R,SUN Z C,et al. Utility of baseline,in⁃
SUVmax is related to tumor cell proliferation and patient terim and end⁃of⁃treatment 18F⁃FDG PET/CT in extranod⁃
outcome in follicular lymphoma [J]. Haematologica, al natural killer/T⁃cell lymphoma patients treated with L⁃
2022,107(1):221-230 asparaginase/pegaspargase[J]. Sci Rep,2017,7:41057
[11] 高珂梦,李天女,丁重阳,等. 肺小细胞癌18F⁃FDG PET [20] BOELLAARD R,DELGADO⁃BOLTON R,OYEN W J,et
代谢参数与相关代谢指标的关系[J]. 南京医科大学学 al. FDG PET/CT:EANM procedure guidelines for tumour
报(自然科学版),2020,40(12):1855-1859 imaging:version 2.0[J]. Eur J Nucl Med Mol Imaging,
[12] LI H Y,SHAO G Z,ZHANG Y J,et al. Nomograms based 2015,42(2):328-354
on SUVmax of 18F⁃FDG PET/CT and clinical parameters [21] SUZUKI R,SUZUMIYA J,YAMAGUCHI M,et al. Prog⁃
for predicting progression⁃free and overall survival in pa⁃ nostic factors for mature natural killer(NK)cell neo⁃
tients with newly diagnosed extranodal natural killer/T ⁃ plasms:aggressive NK cell leukemia and extranodal NK
cell lymphoma[J]. Cancer Imaging,2021,21(1):9 cell lymphoma,nasal type[J]. Ann Oncol,2010,21(5):
[13] XIA X W,WANG Y Q,YUAN J J,et al. Baseline SUV⁃ 1032-1040
max of 18F⁃FDG PET⁃CT indicates prognosis of extranod⁃ [22] KIM S J,YOON D H,JACCARD A,et al. A prognostic in⁃
al natural killer/T ⁃ cell lymphoma[J]. Medicine(Balti⁃ dex for natural killer cell lymphoma after non⁃anthracy⁃
more),2020,99(37):e22143 cline⁃based treatment:a multicentre,retrospective analy⁃
[14] XU P P,GUO R,YOU J H,et al. Dynamic evaluation of sis[J]. Lancet Oncol,2016,17(3):389-400
the prognostic value of 18F ⁃ FDG PET/CT in extranodal [23] HONG H M,LI Y X,LIM S T,et al. A proposal for a new
NK/T⁃cell lymphoma,nasal type[J]. Ann Hematol,2021, staging system for extranodal natural killer T⁃cell lympho⁃
100(4):1039-1047 ma:a multicenter study from China and Asia Lymphoma
[15] BARRINGTON S F,MEIGNAN M. Time to prepare for Study Group[J]. Leukemia,2020,34(8):2243-2248
risk adaptation in lymphoma by standardizing measure⁃ [收稿日期] 2022-07-19
ment of metabolic tumor burden[J]. J Nucl Med,2019,60 (本文编辑:唐 震)